AstraZeneca spearheads lung cancer alliance aiming to boost survival rates - FiercePharma

AstraZeneca spearheads lung cancer alliance aiming to boost survival rates  FiercePharma

AstraZeneca wants to double the five-year lung cancer survival rate by 2025. That's an ambitious target for a disease that's the leading cause of cancer deaths in ...